VTv Therapeutics Appoints CFO Amid Phase 3 Oral Diabetes Trial

vTv Therapeutics Inc., a late-stage biopharmaceutical company, has appointed Michael Tung, M.D., MBA, as Executive Vice President and Chief Financial Officer amid the reinitiation of its CATT1 Phase 3 trial for cadisegliatin, an oral adjunctive therapy to insulin for type 1 diabetes (T1D). Dr. Tung brings over 20 years of diversified experience in finance, corporate strategy, investor relations, and business development within the biopharmaceutical industry, including prior roles at AdvanCell Pty Limited, FibroGen Inc., and Aclaris Therapeutics. The appointment is seen as a strategic move to provide financial leadership as the company advances its clinical development program, which targets improved glycemic control through a novel glucokinase activator. vTv's CEO, Paul Sekhri, highlighted Dr. Tung's capital markets expertise and industry knowledge as vital for guiding the company during this critical phase. Dr. Tung expressed enthusiasm about joining vTv at a pivotal time, emphasizing his commitment to enhancing shareholder value and supporting the company's strategic vision. The company’s shares showed positive market activity following the announcement, reflecting investor confidence in its development pipeline and leadership changes.